CFTR and cystic fibrosis: An analogous investigation was subsequently performed by Pedrazzi et al., who analyzed the modifications in the proteomic profile related to restored CFTR activity in PBMCs isolated from CF subjects carrying residual function mutations eligible for Ivacaftor therapy after ex vivo treatment with this potentiator [126].